about
sameAs
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's DiseaseKinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's diseaseMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesOverexpression of semicarbazide-sensitive amine oxidase in human myopathiesVascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseasesVAP-1/SSAO plasma activity and brain expression in human hemorrhagic strokeImmunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitusInvolvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemiaSemicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's diseaseTissue activity and cellular localization of human semicarbazide-sensitive amine oxidase.The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do.Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of AlzheimeMultipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybridsASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease.Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia.Catecholaminergic and cholinergic systems of mouse brain are modulated by LMN diet, rich in theobromine, polyphenols and polyunsaturated fatty acids.Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro.A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.p53 phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1.Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells.Characterization of A7r5 cell line transfected in a stable form by hSSAO/VAP-1 gene (A7r5 hSSAO/VAP-1 cell line).Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.Time-dependent activation of the semicarbazide-sensitive amine oxidase (SSAO) from ox lung microsomes.Prolonged treatment with aminoguanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats.Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species.Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus.A diet enriched in polyphenols and polyunsaturated fatty acids, LMN diet, induces neurogenesis in the subventricular zone and hippocampus of adult mouse brain.PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent neuroprotection in ER stress-induced cell death.Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes.Some properties of semicarbazide-sensitive amine oxidase (SSAO) from human cerebrovascular tissues.Induction of atypical EAE mediated by transgenic production of IL-6 in astrocytes in the absence of systemic IL-6.Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.PP1/PP2A phosphatases inhibitors okadaic acid and calyculin A block ERK5 activation by growth factors and oxidative stress.Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.
P50
Q26744105-F75F7BA6-5205-4082-B085-ACC510060746Q27689558-1E89D337-2DEB-4E13-8139-1289BB751EB3Q28066691-DF86650C-54BB-4DB3-B839-5A3A49CE5256Q28241833-21588CA5-16AA-4BC1-A2A3-525446DBFD1AQ28244962-D21D410F-DFB3-4F96-B345-460DAE75AFE0Q28254480-DC0FBAE8-EE9A-4844-BBA4-66469AECD194Q28269188-A5B5F552-942D-4DD5-8D8B-5D2890694A11Q28307424-3C7B434E-CFB7-4818-B037-DE47D91EC27DQ28568746-6010ED6D-8A54-4681-BE0B-1218AFF05BBDQ31825386-BD29673D-9B1B-43DB-B505-5B49C76BF6A5Q32052752-87176D13-D455-4E4A-AEC9-6D3E223AF1F2Q33974883-40A1922C-96FB-44D0-A59C-4D66EC7AE2D0Q34056563-73BDE4BD-2EAF-474F-9DC9-0990F416D547Q34394212-B1137C13-7263-4DEA-A0D9-90013D1729EDQ37043396-587A5F8D-F66A-4787-86C9-4B450AE8D908Q37942346-EB087267-C3B7-4FD2-A063-CAF037F84D58Q38067297-B5B7B634-D037-4B64-B141-892C9022E376Q38707023-6799AECD-3AF0-43A8-AE63-277341983486Q38835918-FCDB29BC-BAA5-4311-AB68-B7A760F4696FQ38901622-B502956C-E4DE-4447-9B70-101401506FB8Q39114657-DD073D50-DB9C-415A-92BD-88826FC0ADDEQ39221619-4F2A688E-889E-46F1-A423-633E5726AAD5Q39381722-FA2297BA-CAA8-45A8-9737-9F0C6379D18BQ40001137-EC1F7B0E-3787-481E-BA75-2874DD85825BQ40003995-47ECECC6-3E5D-4259-889C-8A1998A7C41DQ40152752-59213313-1269-4422-BDFB-CCC17EB131EBQ40487244-B725BD32-85E9-4121-8838-CE858978FBF9Q41989322-7969192A-0B0D-460D-8795-82BCD32E7623Q42827655-CD4074EC-1D27-4719-806A-E21AC3D03C50Q43031253-4255DBA9-28CD-4D87-A5A7-6ABF2BBFD45BQ43040072-05941223-8106-44A2-B807-3A3499B93129Q43271864-B4E758B2-6268-41B9-8356-63868AEA4DDAQ43297095-0E0F3245-BF73-4936-9D4D-2EFE2BBCA42BQ43450036-D6ED1F0A-CF5C-4CE8-A2AC-43B4F7CDFBDAQ43575496-B06711DE-7825-47BD-B552-6B0421890825Q43644210-50D9D0C8-004D-4A17-A868-80CD52ACE0DEQ43866456-F4E7C54D-DDBD-4613-9D15-03FA3060A1EDQ43901274-1C7C4AAE-90D6-454A-BB5A-425283C115FEQ44068363-28F481B3-E429-4505-B9E5-4044478F95D3Q44092195-ACB76724-E2AE-44F2-8C38-1DAF9930E07A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mercedes Unzeta
@ast
Mercedes Unzeta
@en
Mercedes Unzeta
@es
Mercedes Unzeta
@nl
type
label
Mercedes Unzeta
@ast
Mercedes Unzeta
@en
Mercedes Unzeta
@es
Mercedes Unzeta
@nl
prefLabel
Mercedes Unzeta
@ast
Mercedes Unzeta
@en
Mercedes Unzeta
@es
Mercedes Unzeta
@nl
P106
P21
P31
P496
0000-0002-7113-3383